Assessment of the treatment effect of pregabalin in patients with post-thoracotomy pai
Not Applicable
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000007713
- Lead Sponsor
- Gifu University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with severe renal impairment 2. Patients with pneumothorax or who received mediastinotomy 3. Patients with interstitial pneumonia 4. Patients with history of a previous ipsilateral thoracotomy 5. Patient who used opioid, gabapentine, and/or pregabalin before surgery 6. Other patients considered to be ineligible to participate in the study by the investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method VAS at week 2 (Pain at rest, or at coughing)
- Secondary Outcome Measures
Name Time Method 1) VAS at day 0 to 7, week 4 and month 3 (Pain at rest, or at coughing) 2) VAS before breakfast, lunch, and dinner at day 2 and 3 (Pain at rest, or at coughing) 3) SF-MPQ (Short-Form McGill Pain Questionnaire) at day 0 and 7, week 2 and 4, and month 3 4) EQ-5D at day 0 to 7, week 2, and 4, and month 3 5) Sleep disorder score (VAS) 6) Incidence of adverse reactions: sleepiness, lightheaded feeling, edema, nausea, vomiting, constipation, and other 7) Number of rescue medication use (codeine phosphate powder 20mg/time and Acetaminophen 400mg/time) 8) Screening tool of neuropathic pain at month 3